A US-based fund seeks to provide debt financing to companies in the life science and healthcare sectors; financing is offered in the forms of senior secured term loans, cash flow loans, revolving lines of credit, real estate and equipment loans. Loans may vary in size from $500,000 to $50m, with ranges and payment terms varying according to the type of loan provided. The firm typically issues about $400-500m in debt per year. Debt is provided to companies for working capital, growth, expansions, recapitalizations, product licensing or acquisitions, or to purchase equipment or real estate. The firm considers opportunities in the USA, Canada, Europe and Oceania.
In the life science sector, the firm is most interested in companies developing therapeutics and medical devices. The firm considers lending to therapeutic companies with a product in Phase I development or later, or to device companies in clinical development or later.
The firm provides capital to both revenue generating and pre-revenue companies. Typically, capital is deployed to bring a company to the next inflection point (such as break-even or an acquisition). The firm prefers to lend to companies that have already received the backing of a number of institutional investors such as VCs. The ability of these investors to provide follow-on financing, if necessary, is a key part of the evaluation of an opportunity. When considering management teams, the firm prefers those who have prior industry experience.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment